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The use of zinc in medicinal skin cream was mentioned in Egyptian papyri from 2000 BC (for example, the Smith 
Papyrus), and zinc has apparently been used fairly steadily throughout Roman and modern times (for example, as 
the American lotion named for its zinc ore, ‘Calamine’). It is, therefore, somewhat ironic that zinc is a relatively late 
addition to the pantheon of signal ions in biology and medicine. However, the number of biological functions, health 
implications and pharmacological targets that are emerging for zinc indicate that it might turn out to be ‘the calcium 
of the twenty-first century’. Here neurobiological roles of endogenous zinc is summarized.
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INTRODUCTION AND OVERVIEW
In medicine and biology, zinc has several connotations. 
It is an essential micronutrient,
1 a component of enzymes 
and other proteins,
2 and a toxic pollutant
3 as well. 
To neuroscientists, zinc is also an ionic signal, Zn
2＋ 
enters cells through gated channels,
4,5 and moves among 
various organelles and storage depots within cells,
6,7 
modulating protein function by binding to and detaching 
from zinc-dependent proteins.
7-9 Like calcium, excess 
free zinc in tissue is toxic.
10
Zn
2＋ is selectively stored in, and released from, the 
presynaptic vesicles of a specific type of neurons in the 
mammalian brain. These zinc-releasing neurons also 
release glutamate, so the term “gluzinergic” has been 
proposed to describe them.
11,12 By and large, the glu-
zinergic neurons all have their cell bodies in either the 
cerebral cortex or in the limbic structures of the fore-
brain.
13 Thus the gluzinergic neuronal system comprises 
a vast cortical-limbic associational network that unites 
limbic and cerebrocortical functions. The gluzinergic 
message is the exclusive voice of the cerebrocortical and 
limbic systems.
In the fifty years since the first identification of 
chelatable zinc in the brain,
14 a broad outline of the 
function of gluzinergic neurons has slowly come into 
focus. First, zinc appears to modulate the overall excit-
ability of the brain via effects on glutamate, and 
probably GABA receptors. Clinical links to epileptic 
disorders have been a major theme in the literature of 
zinc neurobiology.
15 Secondly, perhaps because it is 
preferentially located in cerebrocortical associational 
pathways, zinc may be important in synaptic plas-
ticity.
16,17
However, excess free zinc ion is toxic. Indeed, a 
major portion of current interest in the neurobiology of 
zinc is driven by the idea that the zinc ion is a causal 
contributor in both the acute brain injury of stroke, head 
trauma, seizures, or cardiac arrest,
10 and the slow and Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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relentless brain injury of the neurodegenerative disorders 
such as Alzheimer’s disease (AD) and possibly amyo-
trophic lateral sclerosis (ALS).
18
In the present paper, current evidence that implicates 
endogenous zinc in pathophysiology of both acute brain 
damage and degenerative brain diseases is reviewed.
BASIC NEUROPHYSIOLOGY OF ZINC
Maske first identified the zinc-containing mossy-fiber 
terminals.
14 Subsequently, it was found that many of the 
intrinsic, glutamatergic pathways of the cerebral cortex 
are comprised of gluzinergic neurons. The “intrinsic” is 
here emphasized because corticofugal and corticopedal 
long-axon pathways, though also glutamatergic, are 
generally devoid of zinc.
Surprisingly little is known about the biological life 
cycle of zinc in the glutamatergic vesicles of the 
forebrain. There is a protein, zinc transporter-3 (ZnT-3), 
that co-localizes with zinc vesicles, and mice lacking the 
gene for that protein (znt-3 knockouts) show no staining 
for zinc in their presynaptic terminals.
19 These data 
indicate that the ZnT-3 protein plays a role in seques-
tering vesicular zinc, but exactly what that role is 
remains uncertain.
20
Like other neurotransmitters packed in vesicles, zinc 
is released with neuronal activity. A number of groups 
have found very robust and reliable release of zinc from 
boutons upon electrical stimulation
21,22 or simple elapsed 
time.
23 Most recently, the release of zinc has been 
elegantly demonstrated on a pulse-by-pulse basis, with 
each action potential releasing zinc.
24
The soma and dendrites of mammalian neurons are 
studded with a variety of zinc-permeable ion channels. 
These include the NMDA channel, voltage-gated 
calcium channels, and the calcium-permeable AMPA/ 
Kainate (Ca-A/K) channel. Zinc influx through these 
channels has been demonstrated.
25-30
Because presynaptic terminals release zinc and the 
postsynaptic soma and dendrites have zinc-permeable 
channels, it follows that zinc ions will travel from inside 
a presynaptic neuron to inside a post synaptic neuron 
(translocate) under favorable conditions. Because both 
glutamate and depolarization open the zinc-permeable 
channels,
4,28-30 one expects the maximum zinc trans-
location during intense neuronal activity with depolari-
zation. Much evidence discussed below indicates that 
such translocation contributes to zinc-induced cell injury 
in excitotoxicity. There is also evidence that a smaller- 
volume translocation may occur during normal physio-
logical synaptic signaling, with the translocated zinc 
perhaps triggering further signal cascades in the post-
synaptic neuron.
31
In addition to the zinc that can be released from 
presynaptic terminals into the extracellular fluid, it is 
clear that there is also a pool of zinc stored in perikarya 
that can be “released” into the cytoplasm. One source of 
this zinc is the metallothionein family of proteins (MTs), 
from which zinc can be released at an especially high 
rate by nitrosylation of the thiol ligands by NO.
32,33 Of 
three isoforms of MTs, MT-3 has only been found in 
brain and testes, whereas the others are more wide-
spread.
34,35 In brain injury, the absence of MT-3 signifi-
cantly reduces cell injury in hippocampal field CA1 and 
the thalamus,
36 implying that zinc released off MT3 can 
contribute to cell injury. In contrast, in hippocampal 
field CA3, the absence of MT-3 increases cell death in 
excitotoxic injury, presumably because the presynaptic 
release of zinc is so pronounced in CA3,
37,38 that the 
postsynaptic MT-3 serves more as a zinc sink than a 
zinc source.
39,40 
One of the very first neuronal receptors found sensi-
tive to Zn
2＋ was the NMDA-type glutamate ionophore, 
which was shown to be inhibited by Zn
2＋ in 1987.
41 
The sensitivity of the NMDA-type receptor-ionophore is 
now understood to be mediated by two separate 
mechanisms, a voltage-independent site on the NR2A 
subunit that has an IC50 in the single-digit nanomolar 
range
42.43 and a less sensitive, voltage-dependent site on 
the NR2B
44 subunit where ionic current is decreased by 
low-micromolar concentrations of Zn
2＋. Another poten-
tially critical aspect of the zinc-NMDA relationship is 
that prior exposure to zinc apparently causes a delayed 
increase in the sensitivity of the receptor to agonists. 
This delayed effect (over hours) is mediated by 
increased phosphorylation of the NR2A and NR2B 




The second receptor that has been studied intensively 
for zinc sensitivity is the GABA receptor, which was 
first shown to be inhibited by Zn
2＋ in 1987.
41,47 
Although most of the data concerning the GABA 
sensitivity to zinc have come from experiments in which 
exogenous zinc was added to tissue baths, several 
exemplary experiments have used the blockade (chelation) 
paradigm to reveal effects of endogenous zinc signals.
48,49 
Changes in the zinc modulation of GABA receptor have 
been implicated in the etiology of epilepsy. Mody, 
Coulter and others
50-52 have suggested that the seizure- 
induced sprouting of zinc-releasing axons into ectopic 
locations could result in ectopic release of zinc, thus 
reducing GABA-A receptor-mediated inhibition, and 
enhancing seizure susceptibility.
51 In addition to the 
sprouting of zinc-releasing axons, there are additional 
changes in zinc modulation of the GABA receptor that 
could contribute to the progressive epileptogenesis.
53,54
ZINC IN ACUTE BRAIN INJURY
1. Zinc accumulation as a cause of neuronal death
Although zinc lacks redox activity, and was traditionally 
regarded as relatively non-toxic,
55 an increasing body of 
evidence demonstrates that zinc is in fact a potent killer 
of neurons and glial cells. As mentioned earlier, the 
toxicity of free zinc (even 1 µM) in streams and oceans 
is well known to environmental scientists.
3,56
In 1986, we have demonstrated that brief (15 min) 
exposure to 300-600 µM zinc results in extensive 
neuronal death in cortical cell culture.
57 Combined with 
the realization that neurons store up to 300 µM of free 
zinc in their terminals
58 and release that zinc when they 
are depolarized,
59-61 the fact that zinc was cytotoxic 
suggested the possibility that zinc might play an active 
role in neuronal injury.
The facts that (i) minutes of exposure to µM zinc kills 
brain cells in culture, and (ii) zinc is massively released 
in acute brain injury, suggest that zinc toxicity could 
contribute to neuronal injury in vivo. Staining of brain 
sections of ischemia- or epilepsy-subjected animals with 
a zinc fluorescent dye and acid fuchsin, revealed a 
striking correlation between zinc accumulation in cell 
bodies and their death. It was demonstrated that both 
neuronal death and zinc accumulation in transient 
cerebral ischemia, were reduced or prevented by an 
extracellular zinc chelator, CaEDTA.
62 Subsequently, the 
principle of endogenous zinc toxicity as a contributing 
mechanism has been examined and determined valid in 
other injury models such as blunt head trauma.
63 focal 
ischemia,
64 oxygen-glucose deprivation in vitro
65 and 
glucose deprivation in vivo.
66
Because histochemically-reactive zinc in synaptic 
vesicles was initially considered the only releasable pool 
of zinc,
67 it was postulated that the zinc that appeared in 
postsynaptic neuronal somata was likely presynaptic zinc 
that had been released and “translocated” into the post-
synaptic neurons. However, while useful for a time, the 
“zinc translocation” hypothesis is now recognized as 
incomplete. First, zinc accumulation in degenerating 
neurons has always been observed to some extent in 
areas only lightly innervated by gluzinergic fibers. For 
instance, thalamic neurons are surrounded by terminals 
that lack vesicle zinc.
11,68 Still, these neurons exhibit 
zinc accumulation following ischemia and seizures.
62,68 
Second, even in znt3-null mice that lack synaptic zinc, 
extensive zinc accumulation in degenerating CA1 and 
thalamic neurons was observed.
69 Finally, the fairly 
recent discovery that extracellular CaEDTA can remove 
zinc from inside of cells and even presynaptic vesicles
70 
(presumably by creating extremely steep transmembrane 
gradients) brought the interpretation of CaEDTA data 
into direct question. Specifically, blockade by CaEDTA 
could no longer be accepted as evidence that the zinc 
had traveled through the extracellular fluids.
Zinc accumulation in degenerating neurons of znt-3- 
null mice indicates that there are other zinc sources 
besides synaptic vesicle zinc. One such source is the 
zinc that can be mobilized off MT-3 (and possibly from 
mitochondria) discussed above. As mentioned previously, 
such intracellular zinc release could lead to a somatic 
release of zinc into the extracellular fluid with subseq-
uent zinc translocation into neighboring cells. The direct 
role of Nitric oxide in releasing this MT3 pool of zinc 
during excitotoxicity was recently demonstrated by Wei.
71Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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2. Zinc-initiated cell death pathways
Regardless of specific sources or routes involved, 
increased levels of reactive or “free” zinc inside cells is 
toxic. This toxic effect of zinc was initially puzzling to 
some because zinc had been considered relatively 
innocuous metal, and zinc was known to inhibit 
apoptosis in diverse cell systems.
72
Although zinc is not an oxidizer, several lines of 
evidence have shown that zinc toxicity is mediated 
largely by oxidative stress. First zinc-induced cell death 
is accompanied by increased levels of superoxides and 
lipoperoxides, markers for oxidative injury.
73-75 Second, 
zinc-induced cell death is attenuated by various 
antioxidative measures.
76,77 Third, free radical-generating 
enzymes such as NADPH oxidase are induced and 
activated after zinc exposure, and their inhibitors 
attenuate zinc toxicity.
78
With brief exposure to high concentrations of zinc, 
neurons exhibit signs of necrosis, such as cell body 
swelling and destruction of intracellular organelles.
73 
However, in less fulminant zinc toxicity, signs of 
apoptosis such as DNA fragmentation and caspase acti-
vation, are also observed.
76,79 The fact that zinc exposure 
induces apoptosis was puzzling, since depletion of zinc 
also induces caspase activation and apoptosis.
80,81 
However, elevated zinc does indeed produce apoptosis, 
and mechanisms for zinc-triggered apoptosis are now 
being identified. For example, in zinc-exposed neurons, 
both p75
NTR and p75
NTR-associated death executor 
(NADE), are Induced,
82 a combination that can induce 
caspase activation and apoptosis.
83 In addition to this 
pathway, zinc can trigger the release of pro-apoptotic 
proteins such as cytochrome C and apoptosis inducing 
factor (AIF) from mitochondria.
84 Whether and how 
much apoptosis contributes to zinc-related acute brain 
injury is unknown. However, in rat models of ischemia 
and seizures where the role of zinc as a neurotoxin is 
likely, p75
NTR and NADE are co-induced in neurons that 
undergo cell death,
82,85 strengthening the possible involve-
ment of this apoptogenic cascade in vivo.
Another pivotal factor in zinc toxicity is nitric oxide 
(NO). NO releases 7 zinc ions from each single MT 
molecule,
86-88 and the brain-specific MT-3 isoform has a 
considerably lower threshold for zinc release by NO 
than the other isoforms.
89,90 Because inhibition of NO 
synthase (NOS) dramatically reduces the release of zinc 
from brain slices,
71 and reduces the appearance of zinc 
staining after hypoglycemic brain injury,
66 it is clear that 
NO release of zinc from MT plays a crucial role in 
excitotoxic zinc toxicity. NO also rapidly releases zinc 
from presynaptic terminals,
91 thus contributing to cell 
death via the zinc translocation mechanism. Whereas 
NO releases zinc, elevated Intracellular zinc also induces 
and activates neuronal NOS in cultured cortical neurons.
92 
Thus regardless whether zinc or NO is the initial trigger, 
a destructive cycle is easily induced.
The final pathway to zinc-induced cell necrosis seems 
to be poly-ADP-ribose polymerase (PARP) activation,
92 
as in other cases of predominantly necrotic cell death.
93 
DNA damage induced by oxidative and nitrosative 
stresses activates PARP, an enzyme that transfers the 
ADP- ribose moiety from NAD
＋ to various target 
proteins. Since up to several hundred moieties are 
transferred to a molecule of protein, continued activation 
of PARP results in a drastic depletion of NAD
＋ and 
ATP.
94 Consistent with the idea that PARP activation is 
limited only to necrosis type cell death,
93 chronic 
exposure to low concentrations of zinc, which 
preferentially induces apoptosis,
79 is not attenuated by 
deletion of PARP-1.
95
ZINC IN NEURODEGENRATIVE DISEASES
1. Alzheimer’s Disease
Alzheimer’s disease (AD) is characterized by loss of 
cortical neurons and progressive deterioration of cognitive 
function, memory, and self-care. The pathological 
hallmark of AD is marked accumulation of amyloid-β 
(Aβ) protein, neurofibrillary tangles (NFTs) and neuropil 
threads in the neocortex.
96 A β (39-43 amino acid 
residues, ~4 kDa), is the main constituent of both senile 
plaques and cerebrovascular amyloid deposits.
97,98 The 
Aβ peptide is produced from the proteolytic cleavage of 
a much larger transmembrane precursor, the Amyloid 
Protein Precursor (APP).
98 Mutations of APP (on Koh JY. Endogenous Zinc in Neurological Diseases 
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chromosome 21) within or adjacent to the Aβ domain 
cause aggressive familial AD, indicating that abnormal 
Aβ and APP metabolism can give rise to the disease. 
Since the discovery that Zn
2＋ precipitates Aβ,
99,100 
considerable evidence has emerged that free Zn
2＋ in the 
extracellular fluid induces amyloid deposition. Aβ1-40 
specifically and saturably binds zinc with a 1 : 1 (zinc :
Aβ) stoichiometry. Because zinc concentrations of the 
extracellular brain milieu are apparently in 1 to 10 nM 
range, one would expect Aβ1-40 to bind very little zinc 
under normal conditions. However, events leading to a 
sustained increase in extracellular zinc levels, such as a 
transient hypoperfusion, head trauma, or even local 
paroxysmal neuronal firing
101 could easily lead to zinc 
binding to Aβ.
The zinc binding site was mapped to a stretch of 
contiguous residues between positions 6-28 of the Aβ 
sequence, and the histidine at residue 13 plays a critical 
role in Zn
2＋ mediated aggregation.
102 Occupation of the 
zinc binding site, which straddles the lysine 16 position 
of  α -secretase cleavage,
103 by zinc inhibits β-secretase 
type cleavage and so may influence the generation of Aβ 
from APP, and may increase the biological half-life of 
Aβ by protecting the peptide from proteolytic attack.
99 




precipitation is completely reversed with chelation treat-
ment.
104 
Zinc-induced Aβ precipitation at pH 7.4 is highly 
specific for zinc; however, Cu
2＋ and Fe
3＋ can induce 
partial aggregation at pH 7.4 which increases substan-
tially under mildly acidic conditions (pH 6.6).
105 Raman 
spectroscopy has recently shown that Zn
2＋ binds to the 
N(tau) atom of the histidine imidazole ring and that the 






2＋ through selective binding 
sites. When synthetic Aβ is coincubated with excess but 
equal amounts of Cu
2＋ and Zn
2＋,  ≈1.5 equivalents of 
each metal ion binds to each mole of peptide. Because 
the affinity of the Cu
2＋ binding sites on Aβ is much 
higher than that of Zn
2＋ binding sites, the finding that 
Cu
2＋ does not compete for all of the available metal 
binding sites when co-incubated with Zn
2＋ implies that 







2＋ are markedly 
enriched in amyloid plaques,
108 but only Cu and Zn 
co-purify with Aβ extracted from post-mortem human 
brain
109 and have been determined by Raman spectro-
scopy to coordinate with Aβ in plaques.
110
In mouse brain Cu
2＋ and Fe
2＋ levels rise with age.
111 
One idea is that Aβ, which can bind up to 3.5 moles of 
Cu and Zn per monomer
108 becomes hypermetallated 
(overloaded) with age, and abnormally oxidized while 
handling Cu
2＋ physiologically.
18 Such a hypothetical 
abnormal binding of Cu
2＋ to Aβ would yield two 
adverse outcomes: (i) toxicity mediated by redox activity, 
and (ii) oxidative modification of Aβ.
Aβ:C u
2＋ complexes are strongly reducing, and 
generate H2O2 catalytically from biological reducing 
agents including cholesterol.
109,112,113 The redox activity 
is stronger for human Aβ1-42, than human 1-40 or the 
rat Aβ peptide, correlating with the toxicity of the 
peptide in cell culture.
114
Cu
2＋-mediated oxidation of Aβ causes damage to 
histidine and tyrosine side-chains,
115 dityrosine cross-
linking
116 and sulfoxidation of the sole methionine at 
residue 35.
117 This latter methionine is essential for 
keeping metallated Aβ in its normal (redox-silent) 
location within lipid membranes.
118,119 Therefore, 
oxidation of the Aβ by Cu
2＋ may be the first step in 
liberating Aβ species that can later be precipitated by 
Zn
2＋. This may explain why virtually all of the Aβ that 
deposits in the brain in AD is oxidized.
120
Generation of H2O2 by soluble, but oxidized forms of 
Aβ,
121 may explain the association of brain Aβ accumu-
lation with the severe peroxidative damage that is 
characteristic of the AD-affected brain.
122
Events leading to a sustained increase in extracellular 
zinc in combination with oxidative stress, such as stroke, 
head trauma, cardiac arrest, or epilepsy, would increase 
the likelihood of soluble Aβ precipitation into plaque 
and are indeed risk factors for AD.
Zn/Cu chelators reverse Zn/Cu-induced aggregation of 
synthetic Aβ  in vitro,
104 inhibit Aβ-mediated H2O2 
formation,
109,113,123,124 and solubilize Aβ from amyloid 
deposits in post-mortem AD-affected brain tissue.
122 
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in the Tg2576 mouse model of AD have provided 
evidence that synaptically-released zinc underlies amyloid 
pathology in this model. We found that the complete 
absence of any staining for synaptic vesicle zinc in the 
knockout mouse was accompanied by a reduction of the 
cerebral plaque load by approximately 80%.
125 Interest-
ingly, synaptic zinc levels (as measured by histo-
fluorescence for zinc) as well as plaque loads increased 
to a greater degree with age in female mice than in 
male, suggesting the influence of sex hormones on 
synaptic zinc levels.
125 Preliminary evidence suggests 
that estrogen may reduce the level of synaptic vesicle 
zinc, perhaps by modulating the expression level of the 
adaptor protein 3 (AP3) complex, which is required for 
the correct insertion of ZnT3 into vesicular membrane.
126 
Cerebral amyloid angiopathy (CAA) is also decreased in 
ZnT-3 knock outl/Tg2576 compared to Tg2576 controls.
2. Amyotrophic Lateral Sclerosis (ALS)
Two abnormalities of zinc-metalloproteins have impli-
cated zinc in the pathophysiology of ALS (lou Gehrig’s 
dsease). First, it is the well-established fact that familial 
form of ALS in man is accompanied by mutations in the 
metalloenzyme Cu- -Zn-superoxide dismutase (SOD).
127,128 
Mutations in SOD are also associated with ALS- 
resembling spinal motor defects in mice, with different 
mutants having different amounts of wild-type enzymatic 
activity, ranging from 0% (e.g. H46R and G85R) to 
100% (e.g. G37R). SOD1 knockout mice do not develop 
the ALS phenotype,
129 and the age of onset and duration 
of disease in ALS transgenic mice is unaffected by 
levels of wild-type SOD1 activity.
129 Thus, the toxicity 
of mutant SOD1 (mSOD1) is a gain-of-function.
Several gain-of-function redox reactions have been 
proposed for mSOD1, and at least two currently appear 
plausible. Increased peroxidase activity has been reported 
in vitro
130,131 in the H48Q, A4V, and G93A variants, 
although not consistently.
132 Increased peroxidase activity 
in vivo has been reported in the A4V and G93A
132 
species. Cu replete, Zn deficient SOD1 has been reported 
to confer toxicity by producing peroxynitrite according 
to these reactions, and loss of Zn from mSOD1 has been 
proposed as a primary pathogenic event.
133
The second zinc metalloprotein that is aberrant in 
ALS patients is metallothionein, immunoreactivity to 
which is elevated in the brain and liver.
127,128 The same 
pattern of elevated metallothionein immunoreactivity 
occurs in a transgenic model of ALS: SOD1-G93A 
transgenic mice demonstrate increased MT-1, MT-2, and 
MT-3 expression in astrocytes and increased MT-3 in 
neurons.
134 Metallothionein elevation is likely compen-
satory and protective. In the G93A mutant SOD1 
transgenic model of ALS, deficiency of MT-1, MT-2 or 
MT-3 exacerbates the ALS phenotype.
135,136
ZINC AS A THERAPEUTIC TARGET 
IN NEUROLOGICAL DISEASES
1. Buffering Free Zinc
There are three general directions for effective 
zinc-based drug development. (i) Zinc buffers with equili-
brium constants at the optimal value, preventing excess 
zinc damage while avoiding zinc deficiency of the brain; 
(ii) for acute brain injuries (stroke, trauma, ischemia, 
hypo-perfusion), a very short-lived chelator with tighter- 
binding compounds that allow some control of zinc 
toxicity with minimal untoward effects of lowered zinc; 
(iii) “pro-buffers” or “tethered buffers” which could be 
designed to act upon zinc only whenever or wherever 
such zinc buffering is therapeutically required
The first strategy, that of using a relatively weak 
chelator, has already produced promising results. The 
quinoline compound clioquinol, which binds zinc in the 
mid nanomolar range, has been shown to reduce the 
amount of amlyoid plaque in transgenic mice dramati-
cally
137,138 and to slow the rate of cognitive decline in 
human patients
18,139 with AD. Unfortunately, the phase 
III trial with clioquinol was discontinued due to a 
problem in the manufacturing process. Other candidate 
chelators are considered as alternatives.
Another promising use of the low-affinity approach 
has been reported for acute zinc-toxicity. In those studies 
it was shown that, pyrithione (Kd~1 µM) can rescue 
cultured cells from zinc toxicity if administered at 
the right time.
140,141 Pyrithione moves freely through Koh JY. Endogenous Zinc in Neurological Diseases 
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membranes and presumably transports free zinc down its 
concentration gradient, thus rescuing cells from zinc 
toxicity when intracellular zinc levels are higher than 
extracellular zinc levels.
The idea of a “pro-drug chelator” is also under active 
investigation as a treatment for Alzheimer’s disease. In 
this case, a classical strong chelator (BAPTA) has been 
rendered lipophilic and inactive by the addition of alkyl 
chains. Once through the blood brain barrier and 
embedded in a cell wall (lipid membrane) the non- 
chelating drug (DP-109) can be transformed into the 
active BAPTA by membrane lipases. Hence it is 
expected that DP-109 will chelate metals predominantly 
in the vicinity of cell membranes. In Tg2576 mice, 
DP-109 significantly reduced Aβ plaque load by about 
60-80% without noticeable side effects.
68 A related 
compound (DPb99) has also been tested in small 
samples of human patients as a neuroprotective qagainst 
the zinc-mediated injury in stroke, and during the 
coronary bypass surgery.
2. Downstream Control of Zinc-Triggered Toxic 
Signals
Therapies targeting later events are also promising. As 
discussed above, diverse serial and parallel events 
contribute to zinc-induced cell death. First, as zinc 
toxicity is largely mediated by oxidative and nitrosative 
stress,
73,75,92,142 antioxidants and NOS inhibitors may be 
useful. 
Another approach would target inhibition of PARP, 
which appears to be a key downstream event in zinc 
toxicity,
92,95 may be effective in reducing zinc toxicity. 
Third, anti-apoptosis measures such as caspase inhibition 
may be a possibility. Although these mechanisms have 
been demonstrated to contribute to zinc toxicity in cell 
culture, they are considered more or less general mecha-
nisms of cell death in acute brain injury. At the moment, 
it is not known whether any particular neuroprotectant is 
better against zinc toxicity than other injury mechanisms. 
Hence, more studies may be needed to zoom in on drug 
targets that are more specific to zinc toxicity.
Pyruvate protects against zinc-induced cell death in 
cortical culture
143 and oligodendrocyte progenitor cell 
culture.
144 Pyruvate protection is somewhat specific to 
zinc toxicity, because pyruvate does not attenuate 
calcium- overload excitotoxicity in the same cortical 
cell culture.
145 Consistently, in a rat model of transient 
global ischemia where the role of zinc is established,
62 
pyruvate almost completely blocks zinc accumulation as 
well as neuronal death throughout the brain.
145 Pyruvate 
also reduces retinal cell death following zinc exposure in 
culture or following pressure-induced ischemia in rats.
146 
Protection by pyruvate against zinc-triggered cell death 
is applicable not only to neurons and glial cells, but also 
to pancreatic beta cells. Streptozotocin-induced beta cell 
death to which paracrine toxic effect of endogenous zinc 
contributes, is markedly attenuated by pyruvate adminis-
tration.
147 Direct antioxidative effect and/or normaliza-
tion of NAD
＋ levels may contribute to cytoprotection 
by pyruvate.
143,148
Another possible neuroprotectant with specificity 
against zinc-mediated injury is tPA, which is currently 
used for thrombolysis in human patients.
149 Although 
most of tPA’s biological effect, including its excitotoxicity- 
potentiating effect, is mediated by its protease action,
150 
blockade of zinc toxicity by tPA takes place even in the 
presence of excess protease inhibitors.
151 Although the 
protective mechanism is still unclear, tPA had no effect 
on zinc influx into cells, excluding the possibility that 
the protection occurs by the chelation of zinc in the 
media. Rather, a subsequent study showed that tPA 
increases zinc influx into cells.
152 A preliminary result 
suggests that certain membrane receptors with tyrosine 
kinase activity may mediate this effect, since EGF 
receptor tyrosine kinase inhibitor C56 can reverse the 
protection (Koh unpublished). If the effective moiety and 
its cognate membrane receptors can be identified, develop-
ment of tPA-derived peptides that prevent zinc toxicity, 
may be a possibility.
CONCLUSION
Like calcium, zinc is proving to be an essential and 
ubiquitous ionic signal in a myriad of cells and tissues. 
Because fluorescent calcium probes frequently respond 
to zinc as well, separating calcium signals from zinc Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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signals will be mandatory in future research. Therapies 
based on manipulating zinc signals by preventing 
release, blocking channels, altering transport and buffe-
ring zinc of target tissues are all likely to have 
increasingly important roles in twenty-first century 
medicine.
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